Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer

[1]  G. Giaccone,et al.  Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia , 2012, Clinical Cancer Research.

[2]  M. Ychou,et al.  Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Rudek,et al.  Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients , 2012, Investigational New Drugs.

[4]  S. Shurtleff,et al.  Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[6]  T. Conroy,et al.  Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Baker,et al.  Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  M. Santoro,et al.  Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells , 2010, Clinical Cancer Research.

[9]  W. Messersmith,et al.  New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways , 2010, Clinical Cancer Research.

[10]  M. McDevitt,et al.  A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias , 2010, Leukemia.

[11]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[12]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[13]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[15]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Jimeno,et al.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[17]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jeffrey W. Clark,et al.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.

[19]  M. Hidalgo,et al.  A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  C. Unger,et al.  Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. , 2007, European journal of cancer.

[21]  F. Peale,et al.  Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.

[22]  M. Radtke,et al.  Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics , 2006, Cancer Chemotherapy and Pharmacology.

[23]  D. Strumberg,et al.  Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. , 2005, Clinical colorectal cancer.

[24]  J. Nortier,et al.  Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan , 2005, Clinical Cancer Research.

[25]  Jing-Yuan Fang,et al.  The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.

[26]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[27]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[28]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[29]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Goldbohm,et al.  K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.

[31]  M. Leppert,et al.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.